BofA upgraded Tandem Diabetes (TNDM) to Neutral from Underperform with a price target of $30, up from $15. Tandem is moving more into the pharmacy channel and shifting more to a pay as you go business model, notes the analyst, who sees it becoming a more profitable company over the next two years. Tandem is saying its leading indicator, new starts, will finally return to growth and that it sees accelerated revenue growth in 2027, the analyst added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes Care: Solid Q4 Beat Offset by PayGo Transition Uncertainty and Competitive Headwinds Supporting Hold Rating
- Tandem Diabetes price target raised to $21 from $14 at Piper Sandler
- Tandem Diabetes reports Q4 EPS (1c), consensus (9c)
- Tandem Diabetes sees FY25 revenue $1.065B to $1.085B, consensus $1.10B
- Tandem Diabetes up 11% at $20.59 after Q4 results and guidance